Manisha Bhutani, MD
Internal Medicine · Fishkill, NYNPI 1679662464
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $11,531 of the $15,562 with a category attached, or 74.1%. 45 manufacturers reported payments, led by Tosoh Bioscience, Inc. at 25.7% of the total. Reporting peaked in 2019 at $5,711 and has fallen 52.6% since, to $2,706 in 2025. Among internal medicine clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 447 payments — averaging $34.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tosoh Bioscience, Inc.$4K
- AstraZeneca$2K
- Novo Nordisk$2K
- GSK$1K
- Boehringer Ingelheim$1K
- Lilly USA, LLC$696
- plus $4K from 39 others
Across 6 payments — averaging $62,628 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$376K
What the payments were for
- Food & beverage$11,53174%
- Education$250%
- Gifts$4,00626%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TES, ST AIA-PACK$4,006
- 25-OH Vitamin D ST AIA-Pack$4,006
- TSH, ST AIA-PACK$4,006
- TEZSPIRE$1,156
- RYBELSUS$375
- AIRSUPRA$375
- Wegovy$249
- SHINGRIX$228
- FREESTYLE LIBRE 3$193
- AVANCE NERVE GRAFT$140
- EVENITY$125
- OFEV$125
- SUNOSI$125
- Repatha$125
- NEXLIZET$125
- NEXLETOL$125
- JARDIANCE$125
- Kerendia$125
- NUCALA$125
How this compares
$15,562 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 101 | $200,712 |
| EliquisApixaban | 49 | $51,267 |
| FarxigaDapagliflozin Propanediol | 31 | $44,810 |
| JardianceEmpagliflozin | 23 | $35,843 |
| JanuviaSitagliptin Phosphate | 20 | $32,324 |
| XareltoRivaroxaban | 25 | $31,624 |
| JanumetSitagliptin Phos/Metformin Hcl | 22 | $25,612 |
| TrulicityDulaglutide | 18 | $24,740 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $17,578 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $6,659 |
| SynthroidLevothyroxine Sodium | 87 | $6,381 |
| Atorvastatin Calcium | 437 | $5,828 |
| Levothyroxine Sodium | 341 | $4,965 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 83 | $3,572 |
| Duloxetine Hcl | 56 | $2,907 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog Mix 70-30 | $1,986 | $203,485114 claims |
| MerckJanuvia, Janumet | $53 | $57,93642 claims |
| PfizerEliquis, Paxlovid | $289 | $52,69661 claims |
| AstraZenecaFarxiga | $2,236 | $44,81031 claims |
| Boehringer IngelheimJardiance | $1,046 | $35,84323 claims |
| Johnson & JohnsonXarelto | $112 | $31,62425 claims |
| Lilly USA, LLCTrulicity | $696 | $24,74018 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $1,248 | $24,23743 claims |
| AbbVieSynthroid | $671 | $6,38187 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $95 | $4,965341 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Fishkill
- David DoveEast Hampton$12.3M
- Bruce BergerBrooklyn$3.4M
- Nicholas RobinsonBuffalo$2.9M
- Stephen SaletanNew York$2.6M
- Ziad AliNew York$2M
- Scott BeegleAlbany$1.9M
- Anthony MartinezBuffalo$1.6M
- Javier MoralesGreenvale$1.3M
- Ricky HsuNew York$1M
- James UnderbergNew York$953K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.